Yuichi Takashi
Overview
Explore the profile of Yuichi Takashi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
456
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nagata D, Takashi Y, Yamamoto M, Toyokawa K, Makihata K, Koganemaru H, et al.
Intern Med
. 2025 Mar;
PMID: 40058863
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome that results from tumors that secrete fibroblast growth factor 23 (FGF23). This leads to chronic hypophosphatemia. Burosumab, an anti-FGF23 antibody, is an...
2.
Hidaka N, Inoue K, Kato H, Hoshino Y, Koga M, Kinoshita Y, et al.
JACC Adv
. 2024 Jun;
3(1):100747.
PMID: 38939808
Background: In patients with chronic kidney disease (CKD), fibroblast growth factor (FGF)-23 is suspected to cause death or cardiovascular disease by inducing left ventricular hypertrophy (LVH). Objectives: This study aims...
3.
Tsukamoto S, Kobayashi K, Toyoda M, Tone A, Kawanami D, Suzuki D, et al.
Diabetes Obes Metab
. 2024 May;
26(8):3248-3260.
PMID: 38764356
Aim: To conduct a post hoc subgroup analysis of patients with type 2 diabetes (T2D) from the RECAP study, who were treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor and glucagon-like peptide...
4.
Takashi Y, Kawanami D, Fukumoto S
Curr Opin Endocrinol Diabetes Obes
. 2024 Apr;
31(4):170-175.
PMID: 38687287
Purpose Of Review: Fibroblast growth factor 23 (FGF23) is a hormone to reduce blood phosphate concentration. Excessive actions of FGF23 induce FGF23-related hypophosphatemic disorders, such as X-linked hypophosphatemic rickets (XLH)...
5.
Muta Y, Kobayashi K, Toyoda M, Tone A, Suzuki D, Tsuriya D, et al.
Front Pharmacol
. 2024 Apr;
15:1358573.
PMID: 38601470
Accumulating evidence has demonstrated that both SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP1Ra) have protective effects in patients with diabetic kidney disease. Combination therapy with SGLT2i and GLP1Ra is...
6.
Takashi Y
Endocr J
. 2024 Mar;
71(4):335-343.
PMID: 38556320
Bone secrets the hormone, fibroblast growth factor 23 (FGF23), as an endocrine organ to regulate blood phosphate level. Phosphate is an essential mineral for the human body, and around 85%...
7.
Tanaka Y, Soen S, Hirata S, Okada Y, Fujiwara S, Tanaka I, et al.
J Bone Miner Metab
. 2024 Mar;
42(2):143-154.
PMID: 38538869
Introduction: Although synthetic glucocorticoids (GCs) are commonly used to treat autoimmune and other diseases, GC induced osteoporosis (GIOP) which accounts for 25% of the adverse reactions, causes fractures in 30-50%...
8.
Sawatsubashi S, Takashi Y, Endo I, Kondo T, Abe M, Matsumoto T, et al.
Bone
. 2024 Feb;
182:117057.
PMID: 38412893
Excessive actions of FGF23 cause several kinds of hypophosphatemic rickets/osteomalacia. It is possible that there still remain unknown causes or mechanisms for FGF23-related hypophosphatemic diseases. We report two male cousins...
9.
Kobayashi K, Toyoda M, Tone A, Kawanami D, Suzuki D, Tsuriya D, et al.
Diab Vasc Dis Res
. 2023 Dec;
20(6):14791641231222837.
PMID: 38096503
Aims: Combination therapy with sodium-glucose cotransporter inhibitors (SGLT2is) and GLP-1 receptor agonists (GLP1Ras) is now of interest in clinical practice. The present study evaluated the effects of the preceding drug...
10.
Kato H, Koga M, Kinoshita Y, Hidaka N, Hoshino Y, Takashi Y, et al.
J Endocr Soc
. 2022 Dec;
7(2):bvac181.
PMID: 36540156
Context: Tumor-induced osteomalacia (TIO) is one of the most common forms of acquired fibroblast growth factor 23 (FGF23)-related hypophosphatemia and is usually caused by phosphaturic mesenchymal tumors (PMTs). Although the...